Volume 11,Issue 2
Research Progress of Phagocytosis in CRC Therapy
In recent years, immunotherapy has demonstrated substantial clinical efficacy in the treatment of colorectal cancer (CRC). However, due to factors such as high heterogeneity and drug resistance of CRC, the incidence and mortality of this disease continue to increase annually. Phagocytosis is involved in the regulation of the immune system and plays a crucial role in the development of CRC. Studies have demonstrated that the combination of phagocytosis-related genes with immunotherapeutic regimens exhibits great potential for cancer treatment. Therefore, exploring the mechanism of action and research progress of phagocytosis in CRC provides new insights for developing novel therapeutic strategies and improving the prognosis of CRC patients. This review will summarize the process of phagocytosis, the current status of CRC immunotherapy, and the research progress of phagocytosis-related checkpoints in CRC, aiming to provide assistance for the clinical treatment of CRC.
[1] Schmitt M, Greten FR, 2021, The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol, 21(10):653-667.
[2] Zhao Y, Zhang W, Huo M, et al., 2021, XBP1 Regulates the Protumoral Function of Tumor-Associated Macrophages in Human Colorectal Cancer. Signal Transduction and Targeted Therapy, 6(1): 357.
[3] Locati M, Curtale G, Mantovani A, 2020, Diversity, Mechanisms, and Significance of Macrophage Plasticity. Annual Review of Pathology, 15: 123-147.
[4] Luput L, Licarete E, Sesarman A, et al., 2017, Tumor-Associated Macrophages Favor C26 Murine Colon Carcinoma Cell Proliferation in an Oxidative Stress-Dependent Manner. Oncology Reports, 37(4): 2472-2480.
[5] Vinnakota K, Zhang Y, Selvanesan BC, et al., 2017, M2-like Macrophages Induce Colon Cancer Cell Invasion via Matrix Metalloproteinases. Journal of Cellular Physiology, 232(12): 3468-3480.
[6] Wang D, Wang X, Si M, et al., 2020, Exosome-Encapsulated miRNAs Contribute to CXCL12/CXCR4-Induced Liver Metastasis of Colorectal Cancer by Enhancing M2 Polarization of Macrophages. Cancer Letters, 474: 36-52.
[7] Wei C, Yang C, Wang S, et al., 2019, Crosstalk Between Cancer Cells and Tumor Associated Macrophages Is Required for Mesenchymal Circulating Tumor Cell-Mediated Colorectal Cancer Metastasis. Molecular Cancer, 18(1): 64.
[8] Moradinasab S, Pourbagheri-Sigaroodi A, Ghaffari SH, et al., 2022, Targeting Macrophage-Mediated Tumor Cell Phagocytosis: An Overview of Phagocytosis Checkpoints Blockade, Nanomedicine Intervention, and Engineered CAR-Macrophage Therapy. International Immunopharmacology, 103: 108499.
[9] Gül N, van Egmond M, 2015, Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer. Cancer Res, 75(23):5008-13.
[10] Feng M, Jiang W, Kim BYS, et al., 2019, Phagocytosis Checkpoints as New Targets for Cancer Immunotherapy. Nature Reviews Cancer, 19(10): 568-586.
[11] Peter C, Wesselborg S, Herrmann M, et al., 2010, Dangerous attraction: phagocyte recruitment and danger signals of apoptotic and necrotic cells. Apoptosis : an International Journal on Programmed Cell Death, 15(9):1007-1028.
[12] Tesniere A, Schlemmer F, Boige V, et al., 2010, Immunogenic Death of Colon Cancer Cells Treated with Oxaliplatin. Oncogene, 29(4): 482-491.
[13] Limagne E, Thibaudin M, Nuttin L, et al., 2019, Trifluridine/Tipiracil Plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunology Research, 7(12): 1958-1969.
[14] Gardai SJ, McPhillips KA, Frasch SC, et al., 2005, Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells Through Trans-Activation of LRP on the Phagocyte. Cell, 123(2): 321-334.
[15] Miyanishi M, Tada K, Koike M, et al., 2007, Identification of Tim4 as a phosphatidylserine receptor. Nature, 450(7168):435-9.
[16] Hoppe AD, Swanson JA, 2004, Cdc42, Rac1, and Rac2 Display Distinct Patterns of Activation During Phagocytosis. Molecular Biology of the Cell, 15(8): 3509-3519.
[17] Porat-Shliom N, Kloog Y, Donaldson JG, 2008, A Unique Platform for H-Ras Signaling Involving Clathrin-Independent Endocytosis. Molecular Biology of the Cell, 19(3): 765-775.
[18] Miki H, Suetsugu S, Takenawa T, 1998, WAVE, a Novel WASP-Family Protein Involved in Actin Reorganization Induced by Rac. The EMBO Journal, 17(23): 6932-6941.
[19] Edwards DC, Sanders LC, Bokoch GM, et al., 1999, Activation of LIM-Kinase by Pak1 Couples Rac/Cdc42 GTPase Signalling to Actin Cytoskeletal Dynamics. Nature Cell Biology, 1(5): 253-259.
[20] Nagata S, 2007, Autoimmune Diseases Caused by Defects in Clearing Dead Cells and Nuclei Expelled from Erythroid Precursors. Immunological Reviews, 220(1): 237-250.
[21] Colegio OR, Chu NQ, Szabo AL, et al., 2014, Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid. Nature, 513(7519): 559-563.
[22] Li Z, Li Y, Gao J, et al., 2021, The Role of CD47-SIRPα Immune Checkpoint in Tumor Immune Evasion and Innate Immunotherapy. Life Sciences, 273: 119150.
[23] Chhabra A, Ring AM, Weiskopf K, et al., 2016, Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Sci Transl Med, 8(351): 351ra105.
[24] Murata Y, Saito Y, Kotani T, et al., 2018, CD47-Signal Regulatory Protein α Signaling System and Its Application to Cancer Immunotherapy. Cancer Science, 109(8): 2349-2357.
[25] Chao MP, Alizadeh AA, Tang C, et al., 2010, Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma. Cell, 142(5): 699-713.
[26] Liu Y, Wang Y, Yang Y, et al., 2023, Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther, 8(1):104.
[27] Wu Z, Weng L, Zhang T, et al., 2019, Identification of Glutaminyl Cyclase isoenzyme isoQC as a regulator of SIRPα-CD47 axis. Cell Res, 29(6): 502-505.
[28] Li W, Wang F, Guo R, et al., 2022, Targeting Macrophages in Hematological Malignancies: Recent Advances and Future Directions. Journal of Hematology & Oncology, 15(1): 110.
[29] Gordon SR, Maute RL, Dulken BW, et al., 2017, PD-1 Expression by Tumour-Associated Macrophages Inhibits Phagocytosis and Tumour Immunity. Nature, 545(7655): 495-499.
[30] Chen SH, Dominik PK, Stanfield J, et al., 2021, Dual Checkpoint Blockade of CD47 and PD-L1 Using an Affinity-Tuned Bispecific Antibody Maximizes Antitumor Immunity. Journal for ImmunoTherapy of Cancer, 9(10).
[31] Cai H, Zhang Y, Wang J, et al., 2021, Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1. Frontiers in Immunology, 12.
[32] Blees A, Januliene D, Hofmann T, et al., 2017, Structure of the human MHC-I peptide-loading complex. Nature, 551(7681):525-528.
[33] Lentz RW, Colton MD, Mitra SS, et al., 2021, Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?. Molecular Cancer Therapeutics, 20(6): 961-974.
[34] Barkal AA, Weiskopf K, Kao KS, et al., 2018, Engagement of MHC Class I by the Inhibitory Receptor LILRB1 Suppresses Macrophages and Is a Target of Cancer Immunotherapy. Nature Immunology, 19(1): 76-84.
[35] Cornel AM, Mimpen IL, Nierkens S, 2020, MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers (Basel), 12(7):1760.
[36] Loustau M, Anna F, Dréan R, et al., 2020, HLA-G Neo-Expression on Tumors. Frontiers in Immunology, 11.
[37] Attia JVD, Dessens CE, van de Water R, et al., 2020, The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?. International Journal of Molecular Sciences, 21(22): 8678.
[38] Elghetany MT, Patel J, 2002, Assessment of CD24 Expression on Bone Marrow Neutrophilic Granulocytes: CD24 Is a Marker for the Myelocytic Stage of Development. American Journal of Hematology, 71(4): 348-349.
[39] Chen GY, Tang J, Zheng P, et al., 2009, CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science, 323(5922): 1722-5.
[40] Barkal AA, Brewer RE, Markovic M, et al., 2019, CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature, 572(7769):392-396.
[41] Barkal AA, Brewer RE, Markovic M, et al., 2019, CD24 Signalling Through Macrophage Siglec-10 Is a Target for Cancer Immunotherapy. Nature, 572(7769): 392-396.
[42] Ji K, Zhang Y, Jiang S, et al., 2023, SIRPα Blockade Improves the Antitumor Immunity of Radiotherapy in Colorectal Cancer. Cell Death Discovery, 9(1): 180.
[43] Wang Y, Ni H, Zhou S, et al., 2021, Tumor-Selective Blockade of CD47 Signaling with a CD47/PD-L1 Bispecific Antibody for Enhanced Anti-Tumor Activity and Limited Toxicity. Cancer Immunology, Immunotherapy: CII, 70(2): 365-376.
[44] Yang C, Li S, Chen D, et al., 2024, IMM2520, a Novel Anti-CD47/PD-L1 Bispecific Antibody for Cancer Immune Therapy. Heliyon, 10(21).
[45] Klichinsky M, Ruella M, Shestova O, et al., 2020, Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. Nature Biotechnology, 38(8): 947-953.
[46] Zhang W, Liu L, Su H, et al., 2019, Chimeric Antigen Receptor Macrophage Therapy for Breast Tumours Mediated by Targeting the Tumour Extracellular Matrix. British Journal of Cancer, 121(10): 837-845.
[47] Morrissey MA, Williamson AP, Steinbach AM, et al., 2018, Chimeric Antigen Receptors That Trigger Phagocytosis. eLife, 7: e36688.